Table 3.
Univariate analysis of the time of occurrence of ATO-induced hepatotoxicity
| Clinical characteristics | Hepatotoxic patients (N = 112) | ||
|---|---|---|---|
| Early hepatotoxic patients (within 7 days), no. (%) | Nonearly hepatotoxic patients (within 8–28 days), no. (%) | P | |
| Total | 65 (58.04%) | 47 (41.96%) | |
| Age, years | |||
| > 50 | 18 (50%) | 18 (50%) | 0.236 |
| ≤ 50 | 47 (61.84%) | 29 (38.16%) | |
| Sex | |||
| Female | 28 (52.83%) | 25 (47.17%) | 0.290 |
| Male | 37 (62.71%) | 22 (37.29%) | |
| WBC count, × 109/L | |||
| ≤ 10 | 48 (53.33%) | 42 (46.67%) | 0.041* |
| > 10 | 17 (77.27%) | 5 (22.73%) | |
| Platelet count, × 109/L | |||
| ≥ 30 | 23 (52.27%) | 21 (47.73%) | 0.320 |
| < 30 | 42 (61.76%) | 26 (38.24%) | |
| Hemoglobin level, g/L | |||
| ≥ 80 | 37 (63.79%) | 21 (36.21%) | 0.201 |
| < 80 | 28 (51.85%) | 26 (48.15%) | |
| Fibrinogen level, g/L | |||
| ≥ 1 | 37 (49.33%) | 38 (50.67%) | 0.008** |
| < 1 | 28 (75.68%) | 9 (24.32%) | |
| Prophylactic hepatoprotective agents | |||
| Yes | 4 (18.18%) | 18 (81.82%) | 0.000** |
| No | 61 (67.78%) | 29 (32.22%) | |
| Anti-leukocytosis agents | |||
| Single ATO | 34 (50.00%) | 34 (50.00%) | 0.032* |
| ATO + chemotherapy | 31 (70.45%) | 13 (29.55%) | |
Bold values and * are statistically significant (P < 0.05); Bold values and * are statistically significant (P < 0.01); ATO, arsenic trioxide; a, P-values for categorical variables are from Fisher’s exact test (n < 5)